Pulmonary hypertension

ERN-LUNG

ERN-LUNG is a service oriented network for patients and healthcare providers in rare respiratory diseases across Europe and wants to be the one-stop information hub.

Our vision is to transfer knowledge and develop expertise through education and training, rather than making patients or experts travel.

We want to support and train a new generation of highly skilled care teams for rare diseases oft e respiratory system in all Member States .

ERN-LUNG, in cooperation with ERS, has made available useful info and learning material (e.g. webinars, publications) for you.

Enjoy the content!

Educational resources

ILD

Congress sessions

Symposium, Don't blame your parents: causes of pulmonary hypertension in early life, ERS virtual congress 2020

Download all media

What do we learn from novel genes in pulmonary hypertension? N. Morrell (Cambridge (Cambridgeshire), United Kingdom)
Should we screen for hereditary pulmonary hypertension? D. Montani (Le Kremlin-Bicêtre, France)
Does gender matter in pulmonary hypertension? A. Hemnes (Nashville, United States of America)
Bronchopulmonary dysplasia as a cause of pulmonary hypertension E. Vrijlandt (Groningen, Netherlands)

State of the art session, Pulmonary vascular diseases, ERS virtual congress 2020

Download all media

Drug-related pulmonary hypertension: new threats? D. Montani (Le Kremlin-Bicêtre, France)
PROs: which instruments are available in pulmonary hypertension? J. Pepke-Zaba (Cambridge, United Kingdom)
The metabolic syndrome and pulmonary hypertension A. Hemnes (Nashville, United States of America)
Novel insights into the pathogenesis of pulmonary arterial hypertension M. Humbert (Le Kremlin-Bicêtre, France)

Webinars

ERS statement on chronic thromboembolic pulmonary hypertension M. Delcroix (Leuven, Belgium), G. Simonneau (Le Kremlin-Bicêtre, France), E. Mayer (Bad Nauheim, Germany) Thursday, 18 March 2021
COVID-19 in patients with rare diseases of the respiratory system DG Sante (European commission), T.O. F. Wagner (Frankfurt/Main, Germany), I. Fajac (Paris, France), M. Kreuter (Heidelberg, Germany), G. Verleden (Leuven, Belgium), M. Humbert (Paris, France), Heymut Omran (Münster, Germany) Thursday, 30 April 2020

Interactive e-learning content

	Chronic thromboembolic pulmonary hypertension (CTEPH) M. Delcroix (Leuven, Belgium), A. V. Noordegraaf (Amsterdam, Netherlands) Open

	How to diagnose and manage pulmonary vascular disease A. V. Noordegraaf (Amsterdam, The Netherlands), A. Peacock (Glasgow, United Kingdom) Open

CME tests

Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature Yvonne M. Ende-Verhaar, Suzanne C. Cannegieter, Anton Vonk Noordegraaf, Marion Delcroix, Piotr Pruszczyk, Albert T.A. Mairuhu, Menno V. Huisman, Frederikus A. Klok Eur Respir J , 49 (2) 1601792; DOI: 10.1183/13993003.01792-2016

Webcasts

Exercise stress echocardiography of the pulmonary circulation and right ventricular-arterial coupling in healthy adolescents K. Forton (Bruxelles, Belgium), V. Faoro (Bruxelles, Belgium), R. Naeije (Bruxelles, Belgium)
COVID-19 and the pulmonary circulation A. Simonds (United Kingdom), M. Humbert (France), E. Klok (Netherlands), M. Ackermann (Germany), M. Delcroix (Belgium) Monday, 7 December 2020

Insights on right ventricular dysfunction in World Symposium of Pulmonary Hypertension Group 3 PH F. Rischard (Tucson, AZ, United States of America), K. Highland (Cleveland, OH, United States of America), R. Vanderpool (Tucson, AZ, United States of America), M. Redeva (Cleveland, OH, United States of America), .. And The Pulmonary Vascular Disease Phenomics (pvdomics) Study Group (Bethesda, MD, United States of America)

Phenotype and outcome of PAH patients carrying a TBX4 mutation P. Thoré (Le Kremlin-Bicêtre, France), B. Girerd (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France), M. Ghigna (Le Plessis Robinson, France), M. Eyries (Paris, France), M. Levy (Paris, France), C. Ovaert (Marseilles, France), A. Servettaz (Reims, France), A. Guillaumot (Nancy, France), C. Dauphin (Clermont, France), C. Chabanne (Rennes, France), E. Boiffard (La, France), V. Cottin (Lyon, France), F. Perros (Le Plessis Robinson, France), G. Simonneau (Le Kremlin-Bicêtre, France), S. Olivier (Le Kremlin-Bicêtre, France), F. Soubrier (Paris, France), D. Bonnet (Paris, France), M. Remy Jardin (Lille, France), A. Chaouat (Nancy, France), M. Humbert (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France)
REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH) D. Kiely (Sheffield (South Yorkshire), United Kingdom), E. Cottreel (Allschwil, Switzerland), N. Galiè (Bologna, Italy), J. Marcus (Amsterdam, Netherlands), A. Peacock (Glasgow, United Kingdom), S. Rosenkranz (Cologne, Germany), A. Swift (Sheffield, United Kingdom), A. Tawakol (Boston, United States of America), A. Torbicki (Otwock, Poland), A. Vonk Noordegraaf (Amsterdam, Netherlands), G. Wetherill (Allschwil, Switzerland), R. Channick (Los Angeles, United States of America)
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) A. Boucly (Le Kremlin Bicètre, France), A. Baron (Le Kremlin Bicètre, France), L. Savale (Le Kremlin Bicètre, France), X. Jaïs (Le Kremlin Bicètre, France), F. Picard (Bordeaux, France), V. Cottin (Lyon, France), E. Bergot (Caen, France), C. Dauphin (Clermont-Ferrand, France), A. Bourdin (Montpelliernt-Ferrand, France), A. Chaouat (Nancy, France), P. Roblot (Dijon, France), C. Chabanne (Rennes, France), G. Prévot (Toulouse, France), L. Bertoletti (Saint-Etienne, France), D. Montani (Le Kremlin Bicètre, France), G. Simonneau (Le Kremlin Bicètre, France), M. Humbert (Le Kremlin Bicètre, France), O. Sitbon (Le Kremlin Bicètre, France)
Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON O. Sitbon (Le Kremlin Bicêtre, France), N. Galiè (Bologna, Italy), M. Doelberg (Allschwil, Switzerland), J. Gibbs (London, United Kingdom), M. Hoeper (Hannover, Germany), M. Stefani (Allschwil, Switzerland), S. Mathai (Baltimore, United States of America), V. Mclaughlin (Ann Arbor, United States of America), L. Perchenet (Allschwil, Switzerland), G. Simonneau (Le Kremlin Bicêtre, France), K. Chin (Dallas, United States of America)
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation S. JOSHI (Cambridge, United States of America), J. Liu (Cambridge, United States of America), R. Pearsall (Cambridge, United States of America), P. Andre (Cambridge, United States of America), G. Li (Cambridge, United States of America), R. Kumar (Cambridge, United States of America)
Wrap-up by discussant and discussion M. Humbert (Le Kremlin-Bicêtre, France)
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis (APAP) B. Trapnell (Cincinnati, United States of America), Y. Inoue (Osaka, Japan), F. Bonella (Essen, Germany), C. Morgan (London, United Kingdom), S. Jouneau (Rennes, France), E. Bendstrup (Aarhus, Denmark), I. Campo (Pavia, Italy), S. Papiris (Athens, Greece), E. Yamaguchi (Aichi, Japan), E. Cetinkaya (Istanbul, Turkey), M. Ilkovich (St. Petersburg, Russian Federation), M. Kramer (Petah Tikva, Israel), M. Veltkamp (Nieuwegein, Netherlands), M. Kreuter (Heidelberg, Germany), T. Baba (Yokohama, Japan), C. Ganslandt (Austin, United States of America), I. Tarnow (Austin, United States of America), G. Waterer (Perth, Australia), T. Jouhikainen (Austin, United States of America)
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study M. Hoeper (Hannover, Germany), H. Ghofrani (Giessen, Germany), H. Al-Hiti (Prague, Czech Republic), R. Benza (Columbus, OH, United States of America), S. Chang (Seoul, Republic of Korea), P. Corris (Newcastle upon Tyne, United Kingdom), S. Gibbs (London, United Kingdom), E. Grünig (Heidelberg, Germany), P. Jansa (Prague, Czech Republic), J. Klinger (Providence, RI, United States of America), D. Langleben (Montreal, QC, Canada), V. Mclaughlin (Ann Arbor, MI, United States of America), G. Meyer (Porto Alegre, Brazil), J. Ota-Arakaki (São Paulo, Brazil), A. Peacock (Glasgow, United Kingdom), T. Pulido (Mexico City, Mexico), S. Rosenkranz (Cologne, Germany), D. Vizza (Rome, Italy), A. Vonk-Noordegraaf (Amsterdam, Netherlands), J. White (Rochester, NY, United States of America), M. Chang (Berlin, Germany), F. Kleinjung (Berlin, Germany), C. Meier (Berlin, Germany), K. Paraschin (São Paulo, Brazil), G. Simonneau (Le Kremlin-Bicêtre, France)
Wrap-up by discussant and discussion D. Stolz (Basel, Switzerland)
Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2) L. McGarvey (Belfast, United Kingdom), S. Birring (London, United Kingdom), A. Morice (Cottingham, United Kingdom), P. Dicpinigaitis (New York, United States of America), I. Pavord (Oxford, United Kingdom), J. Schelfhout (Kenilworth, United States of America), A. Martin Nguyen (Kenilworth, United States of America), Q. Li (Kenilworth, United States of America), A. Tzontcheva (Kenilworth, United States of America), B. Iskold (Kenilworth, United States of America), S. Green (Kenilworth, United States of America), C. La Rosa (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America), J. Smith (Manchester, United Kingdom)
Late Breaking Abstract - Randomised trial of ambulatory management of primary spontaneous pneumothorax R. Hallifax (Oxfrod, United Kingdom), E. Mckeown (Reading(Oxfordshire), United Kingdom), P. Sivakumar (London, United Kingdom), I. Fairburn (Dunfermline, United Kingdom), C. Peter (Bath, United Kingdom), A. Leitch (Edinburgh, United Kingdom), M. Knight (watford, United Kingdom), A. Stanton (Swindon, United Kingdom), A. Ijaz (Lancaster, United Kingdom), S. Marciniak (Cambridge, United Kingdom), J. Cameron (Bristol, United Kingdom), A. Bhatta (Blackpool, United Kingdom), K. Blyth (Blackpool, United Kingdom), R. Reddy (Kettering, United Kingdom), M. Harris (Edinburgh, United Kingdom), N. Maddekar (Stoke-on-Trent, United Kingdom), S. Walker (Bristol, United Kingdom), A. West (London, United Kingdom), M. Laskawiec-Szkonter (Oxford, United Kingdom), J. Corcoran (Plymouth, United Kingdom), S. Gerry (Oxford, United Kingdom), C. Roberts (Oxford, United Kingdom), J. Harvey (Bristol, United Kingdom), N. Maskell (Bristol, United Kingdom), R. Miller (London, United Kingdom), N. Rahman (Oxford, United Kingdom)

Novel insights into the pathogenesis of pulmonary arterial hypertension M. Humbert (Le Kremlin-Bicêtre, France)
The metabolic syndrome and pulmonary hypertension A. Hemnes (Nashville, United States of America)
PROs: which instruments are available in pulmonary hypertension? J. Pepke-Zaba (Cambridge, United Kingdom)
Drug-related pulmonary hypertension: new threats? D. Montani (Le Kremlin-Bicêtre, France)
Effects of Ground-Based Walking Training in Pulmonary Hypertension Ö. Ertan (Istanbul, Turkey), G. Kuran Aslan (Istanbul, Turkey), B. Akinci (Istanbul, Turkey), G. Okumus (Istanbul, Turkey)
Bronchopulmonary dysplasia as a cause of pulmonary hypertension E. Vrijlandt (Groningen, Netherlands)
Does gender matter in pulmonary hypertension? A. Hemnes (Nashville, United States of America)
Should we screen for hereditary pulmonary hypertension? D. Montani (Le Kremlin-Bicêtre, France)
What do we learn from novel genes in pulmonary hypertension? N. Morrell (Cambridge (Cambridgeshire), United Kingdom)
Patient with ankylosing spondylitis and pulmonary hypertension A. Anthi (Athens, Greece)
Pulmonary hypertension in a COPD Patient J. Khoury (Elaboun, Israel)
New issues in lung transplantation for pulmonary hypertension M. Delcroix (Leuven, Belgium)
Phenotype and outcome of PAH patients carrying a TBX4 mutation P. Thoré (Le Kremlin-Bicêtre, France), B. Girerd (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France), M. Ghigna (Le Plessis Robinson, France), M. Eyries (Paris, France), M. Levy (Paris, France), C. Ovaert (Marseilles, France), A. Servettaz (Reims, France), A. Guillaumot (Nancy, France), C. Dauphin (Clermont, France), C. Chabanne (Rennes, France), E. Boiffard (La, France), V. Cottin (Lyon, France), F. Perros (Le Plessis Robinson, France), G. Simonneau (Le Kremlin-Bicêtre, France), S. Olivier (Le Kremlin-Bicêtre, France), F. Soubrier (Paris, France), D. Bonnet (Paris, France), M. Remy Jardin (Lille, France), A. Chaouat (Nancy, France), M. Humbert (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France)
Protein truncating mutations in ATP13A3 promote pulmonary arterial hypertension E. Legchenko (Cambridge, United Kingdom), B. Liu (Cambridge, United Kingdom), J. West (Cambridge, United Kingdom), P. Vangheluwe (Leuven, Belgium), P. Upton (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom)
Haploid genetic screening identifies a novel regulator of BMPR2 B. Dunmore (Cambridge, United Kingdom), S. Burr (Cambridge, United Kingdom), P. Upton (Cambridge, United Kingdom), J. Nathan (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom)
Genetic findings in patients with different forms of pulmonary hypertension C. Eichstaedt (Heidelberg, Germany), Z. Saßmannshausen (Heidelberg, Germany), H. Gall (Gießen, Germany), A. Ghofrani (Gießen, Germany), H. Seyfarth (Leipzig, Germany), M. Lerche (Leipzig, Germany), M. Halank (Dresden, Germany), P. Xanthouli (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), K. Milger-Kneidinger (Munich, Germany), S. Rosenkrankz (Cologne, Germany), R. Ewert (Greifswald, Germany), M. Lankeit (Berlin, Germany), T. Lange (Regensburg, Germany), K. Hinderhofer (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
Screening of pulmonary arterial hypertension in BMPR2 mutation carriers D. Montani (Le Kremlin-Bicêtre, France), B. Girerd (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France), P. Laveneziana (Le Kremlin-Bicêtre, France), E. Lau (Camperdown, Australia), A. Bouchachi (Le Kremlin-Bicêtre, France), S. Hascoet (Le Plessis-Robinson, France), S. Gunther (Paris, France), L. Godinas (Le Kremlin-Bicêtre, France), F. Parent (Le Kremlin-Bicêtre, France), C. Guiganbert (Le Kremlin-Bicêtre, France), G. Garcia (Le Kremlin-Bicêtre, France), D. Chemla (Le Kremlin-Bicêtre, France), P. Hervé (Le Kremlin-Bicêtre, France), M. Eyries (Paris, France), F. Soubrier (Paris, France), O. Sitbon (Le Kremlin-Bicêtre, France), G. Simonneau (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France)
New rare variant associations with distinct phenotypes in patients with pulmonary arterial hypertension revealed with Bayesian inference. E. Swietlik (Cambridge, United Kingdom), K. Lutz (Cincinnati , United States of America), D. Greene (Cambridge, United Kingdom), M. Pauciulo (Cincinnati , United States of America), T. Tilly (Cambridge, United Kingdom), D. Pandya (Cambridge, United Kingdom), N. Zhu (New York, United States of America), M. Cogliano (Sheffield , United Kingdom), C. Welch (New York, United States of America), A. Coleman (New York, United States of America), . Bioresource Rare Diseases Consortium (Cambridge, United Kingdom), Y. Shen (New York, United States of America), A. Swift (Sheffield , United Kingdom), W. Chung (New York, United States of America), W. Nichols (Cincinnati , United States of America), N. Morrell (Cambridge, United Kingdom), S. Graf (Cambridge, United Kingdom)
Multi-omic profiling in pulmonary arterial hypertension P. Otero-Núñez (London, United Kingdom), C. Rhodes (London, United Kingdom), J. Wharton (London, United Kingdom), E. Swietlik (Cambridge, United Kingdom), S. Kariotis (Sheffield, United Kingdom), L. Harbaum (London, United Kingdom), M. Dunning (Sheffield, United Kingdom), J. Elinoff (Bethesda, United States of America), N. Errington (Sheffield, United Kingdom), R. Thomson (Sheffield, United Kingdom), J. Iremonger (Sheffield, United Kingdom), G. Coghlan (London, United Kingdom), P. Corris (Newcastle, United Kingdom), L. Howard (London, United Kingdom), D. Kiely (Sheffield, United Kingdom), C. Church (Glasgow, United Kingdom), J. Pepke-Zaba (Papworth, United Kingdom), M. Toshner (Cambridge, United Kingdom), S. Wort (London, United Kingdom), A. Desai (Indianapolis, United States of America), M. Humbert (Paris, France), W. Nichols (Cincinnati, United States of America), . Southgate (London, United Kingdom), D. Trégouët (Bordeaux, France), R. Trembath (London, United Kingdom), I. Prokopenko (Surrey, United Kingdom), S. Gräf (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), D. Wang (Sheffield, United Kingdom), A. Lawrie (Sheffield, United Kingdom), M. Wilkins (London, United Kingdom)
State of the art in pulmonary hypertension M. Delcroix (Leuven, Belgium)
Long-term hemodynamic benefits after ‘treat-to-close’ for intracardiac shunts and pulmonary hypertension R. Vanderpool (Tucson, United States of America), S. Klewer (Tucson, United States of America), F. Rischard (Tucson, United States of America), M. Seckeler (Tucson, United States of America)
Right ventricular stiffness impairs right atrial function in pulmonary arterial hypertension J. Wessels (Amsterdam, Netherlands), S. Mouratoglou (Amsterdam, Netherlands), J. Van Wezenbeek (Amsterdam, Netherlands), J. Marcus (Amsterdam, Netherlands), L. Meijboom (Amsterdam, Netherlands), G. Strijkers (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands)
Determinants of right ventricular diastolic stiffness in precapillary pulmonary hypertension: a cardiac magnetic resonance study A. Bayoumy (Amsterdam, Netherlands), N. J. Braams (Amsterdam, Netherlands), S. A. Mouratoglou (Amsterdam, Netherlands), O. A. Spruijt (Amsterdam, Netherlands), F. S. De Man (Amsterdam, Netherlands), A. Vonk-Noordegraaf (Amsterdam, Netherlands), S. M.A. Jansen (Amsterdam, Netherlands), J. A. Groeneveldt (Amsterdam, Netherlands), B. E. Westerhof (Amsterdam, Netherlands), J. Marcus (Amsterdam, Netherlands), L. J. Meijboom (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands)
Sex differences in the relation between sex hormones and right ventricular function in pulmonary arterial hypertension J. van Wezenbeek (Amsterdam, Netherlands), J. Groeneveldt (Amsterdam, Netherlands), S. Jansen (Amsterdam, Netherlands), A. Heijboer (Amsterdam, Netherlands), M. Goumans (Leiden, Netherlands), H. Bogaard (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands)
Insights on right ventricular dysfunction in World Symposium of Pulmonary Hypertension Group 3 PH F. Rischard (Tucson, AZ, United States of America), K. Highland (Cleveland, OH, United States of America), R. Vanderpool (Tucson, AZ, United States of America), M. Redeva (Cleveland, OH, United States of America), .. And The Pulmonary Vascular Disease Phenomics (pvdomics) Study Group (Bethesda, MD, United States of America)
Exercise stress echocardiography of the pulmonary circulation and right ventricular-arterial coupling in healthy adolescents K. Forton (Bruxelles, Belgium), V. Faoro (Bruxelles, Belgium), R. Naeije (Bruxelles, Belgium)
Late Breaking Abstract - Pulmonary embolism in patients with COVID-19: Time to change thromboprophylaxis paradigm. A. Mahalingam (Basildon, United Kingdom), A. Elsheikh (Basildon, United Kingdom), M. Shafiq (Basildon, United Kingdom), M. Pittman (Basildon, United Kingdom)
Late Breaking Abstract - Pulmonary embolism in patients admitted by COVID-19. Incidence and features. F. Garcia (Getafe, Spain), B. Raboso Moreno (Getafe, Spain), C. Matesanz Lopez (Getafe, Spain), J. Diaz Garcia (Getafe, Spain), C. Acosta Gutierrez (Getafe, Spain), C. Panadero Paz (Getafe, Spain), C. Lopez Riolobos (Getafe, Spain), A. Abad Fernandez (Getafe, Spain), E. Aguilar Rivilla (Getafe, Spain), C. Cañibano Dominguez (Getafe, Spain), J. Santiago Luis (Getafe, Spain), M. Calderon Alcala (Getafe, Spain), A. Ruiz Martin (Getafe, Spain), Z. Vasquez Gambasica (Getafe, Spain), P. Andres Ruzafa (Getafe, Spain), J. Garcia Satue (Getafe, Spain), S. Calero Pardo (Getafe, Spain), M. Rio Ramirez (Getafe, Spain)
Late Breaking Abstract - Thromboembolic complications in COVID-19 patients admitted to two large East London hospitals S. Innes (London, United Kingdom), E. Skyllberg (London, United Kingdom), H. Fielden (London, United Kingdom), A. Khan (London, United Kingdom), D. Cheng (London, United Kingdom), R. Kaiser (London, United Kingdom), A. Ainley (London, United Kingdom)
Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how? M. Remy-Jardin (Lille, France)
In-depth risk stratification in pulmonary arterial hypertension A. Yogeswaran (Giessen, Germany), K. Tello (Giessen, Germany), N. Sommer (Giessen, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), M. Richter (Giessen, Germany), H. Gall (Giessen, Germany)
EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study R. Lewis (Sheffield (South Yorkshire), United Kingdom), I. Armstrong (Sheffield (South Yorkshire), United Kingdom), C. Bergbaum (London, United Kingdom), M. Brewis (Glasgow, United Kingdom), J. Cannon (Cambridge, United Kingdom), A. Charalampopoulos (Sheffield (South Yorkshire), United Kingdom), A. Church (Glasgow, United Kingdom), J. Coghlan (London, United Kingdom), R. Davies (London, United Kingdom), K. Dimopoulos (London, United Kingdom), C. Elliot (Sheffield, United Kingdom), J. Gibbs (London, United Kingdom), W. Gin-Sing (London, United Kingdom), G. Haji (London, United Kingdom), A. Hameed (Sheffield (South Yorkshire), United Kingdom), L. Howard (London, United Kingdom), M. Johnson (Glasgow, United Kingdom), A. Kempny (London, United Kingdom), D. Kiely (Sheffield (South Yorkshire), United Kingdom), F. Lo Giudice (Manchester, United Kingdom), C. Mccabe (London, United Kingdom), O. Peleyeju (London, United Kingdom), J. Pepke-Zaba (Cambridge, United Kingdom), G. Polwarth (Cambridge, United Kingdom), L. Price (London, United Kingdom), I. Sabroe (Sheffield (South Yorkshire), United Kingdom), B. Schreiber (London, United Kingdom), K. Sheares (Cambridge, United Kingdom), D. Taboada (Cambridge, United Kingdom), A. Thompson (Sheffield (South Yorkshire), United Kingdom), M. Toshner (Cambridge, United Kingdom), I. Wanjiku (London, United Kingdom), S. Wort (London, United Kingdom), J. Yorke (Manchester, United Kingdom), R. Condliffe (Sheffield (South Yorkshire), United Kingdom)
Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial E. Grünig (Heidelberg, Germany), A. Mackenzie (Glasgow, United Kingdom), A. Peackock (Glasgow, United Kingdom), C. Eichstaedt (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), R. Nechwatal (Heidelberg, Germany), S. Ulrich (Zurich, Switzerland), S. Saxer (Zurich, Switzerland), M. Bussotti (Milan, Italy), M. Sommaruga (Milan, Italy), S. Ghio (Pavia, Italy), L. Gumbiene (Vilnius, Lithuania), E. Paleviciute (Vilnius, Lithuania), E. Jureviciene (Vilnius, Lithuania), A. Cittadini (Salerno, Italy), A. Stanziola (Naples, Italy), A. Marra (Naples, Italy), G. Kovacs (Graz, Austria), H. Olschewski (Graz, Austria), J. Barberà (Barcelona, Spain), I. Blanco (Barcelona, Spain), M. Spruit (Maastricht, Netherlands), F. Franssen (Horn, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), A. Reis (Porto, Portugal), M. Santos (Porto, Portugal), S. Goncalves Viamonte (Porto, Portugal), H. Demeyer (Leuven, Belgium), M. Delcroix (Leuven, Belgium), E. Bossone (Naples, Italy), M. Johnson (Glasgow, United Kingdom)
REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH) D. Kiely (Sheffield (South Yorkshire), United Kingdom), E. Cottreel (Allschwil, Switzerland), N. Galiè (Bologna, Italy), J. Marcus (Amsterdam, Netherlands), A. Peacock (Glasgow, United Kingdom), S. Rosenkranz (Cologne, Germany), A. Swift (Sheffield, United Kingdom), A. Tawakol (Boston, United States of America), A. Torbicki (Otwock, Poland), A. Vonk Noordegraaf (Amsterdam, Netherlands), G. Wetherill (Allschwil, Switzerland), R. Channick (Los Angeles, United States of America)
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) A. Boucly (Le Kremlin Bicètre, France), A. Baron (Le Kremlin Bicètre, France), L. Savale (Le Kremlin Bicètre, France), X. Jaïs (Le Kremlin Bicètre, France), F. Picard (Bordeaux, France), V. Cottin (Lyon, France), E. Bergot (Caen, France), C. Dauphin (Clermont-Ferrand, France), A. Bourdin (Montpelliernt-Ferrand, France), A. Chaouat (Nancy, France), P. Roblot (Dijon, France), C. Chabanne (Rennes, France), G. Prévot (Toulouse, France), L. Bertoletti (Saint-Etienne, France), D. Montani (Le Kremlin Bicètre, France), G. Simonneau (Le Kremlin Bicètre, France), M. Humbert (Le Kremlin Bicètre, France), O. Sitbon (Le Kremlin Bicètre, France)
Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON O. Sitbon (Le Kremlin Bicêtre, France), N. Galiè (Bologna, Italy), M. Doelberg (Allschwil, Switzerland), J. Gibbs (London, United Kingdom), M. Hoeper (Hannover, Germany), M. Stefani (Allschwil, Switzerland), S. Mathai (Baltimore, United States of America), V. Mclaughlin (Ann Arbor, United States of America), L. Perchenet (Allschwil, Switzerland), G. Simonneau (Le Kremlin Bicêtre, France), K. Chin (Dallas, United States of America)
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation S. JOSHI (Cambridge, United States of America), J. Liu (Cambridge, United States of America), R. Pearsall (Cambridge, United States of America), P. Andre (Cambridge, United States of America), G. Li (Cambridge, United States of America), R. Kumar (Cambridge, United States of America)
ERS statement on chronic thromboembolic pulmonary hypertension M. Delcroix (Leuven, Belgium)
Interventional treatment of pulmonary hypertension: where are we now? N. Galiè (Bologna (BO), Italy)